{
    "nct_id": "NCT03254394",
    "official_title": "Intravenous Lidocaine for Preventing Painful Oxaliplatin-induced Peripheral Neuropathy (OIPN)",
    "inclusion_criteria": "* Stage III and IV colorectal cancer.\n* Scheduled for oxaliplatin treatment in mFOLFOX6-based chemotherapy regimen.\n* Able to understand and willing to sign an IRB-approved written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Renal insufficiency (defined as calculated Creatinine clearance < 30mL/min)\n* Moderate to severe liver failure (defined as ALT or AST > 3 times upper limit of normal if no liver metastases are present; ALT or AST > 5 times upper limit of normal if liver metastases are present).\n* Presence of brain metastases.\n* Patients with currently uncontrolled cardiac arrhythmias (non-sinus rhythm).\n* Patients with history of arrhythmias under pharmacological/pacemaker control will be allowed, except if receiving antiarrhythmic medication listed in \"contra-indicated medications\".\n* Contraindication or allergy to intravenous lidocaine.\n* Pre-existing symmetric peripheral painful neuropathy.\n* Treated with chemotherapy within the past 12 months.\n* Pregnancy or breastfeeding\n* Currently treated with any of the following contraindicated medications: Saquinavir, Lopinavir, Amprenavir, Atazanavir, Delavirdine, Mexiletine (and other types of sodium-channel blocker antiarrhythmics), Phenytoin, Carbamazepine, Oxcarbazepine, Lamotrigine, Amiodarone, Dronedarone, Dihydroergotamine, Cimetidine",
    "miscellaneous_criteria": ""
}